3T Therapy in the Treatment of MDA5-positive Dermatomyositis
Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if a combination of tacrolimus, tafocitinib and thalidomide (3T therapy) works to treat severe MDA5 positive dermatomyositis in adults. It will also learn about the safety of 3T therapy. The main questions it aims to answer are:
Does 3T therapy prolong the overall survival time of MDA5 positive dermatomyositis? What medical problems do participants have when taking 3T therapy?
Participants will:
Take 3T therapy every day for 12 months Visit the clinic once every 2 weeks for checkups and tests
Phase:
PHASE4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University